REPLIMUNE GROUP, INC. Research and Development Expense
REPLIMUNE GROUP, INC. (REPL) reported Research and Development Expense of $49.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- REPLIMUNE GROUP, INC. research and development expense for the quarter ending 2026-06-30 was $49.28M, a 14.81% decline year-over-year.
- REPLIMUNE GROUP, INC. research and development expense for the quarter ending 2026-03-31 was $52.32M, a 3.06% decline year-over-year.
- REPLIMUNE GROUP, INC. research and development expense for the quarter ending 2025-12-31 was $53.14M, a 10.70% increase year-over-year.
- REPLIMUNE GROUP, INC. research and development expense for the quarter ending 2025-09-30 was $57.88M, a 33.21% increase year-over-year.
- REPLIMUNE GROUP, INC. research and development expense for fiscal 2026 was $221.18M, a 16.75% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. research and development expense for fiscal 2025 was $189.45M, a 8.28% increase from fiscal 2024.
- REPLIMUNE GROUP, INC. research and development expense for fiscal 2024 was $174.96M, a 38.28% increase from fiscal 2023.
- REPLIMUNE GROUP, INC. research and development expense for fiscal 2023 was $126.53M, a 59.06% increase from fiscal 2022.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.28M 10-Q · filed 2026-08-14 | $101.60M derived: sum of 2 quarters · filed 2026-08-14 | $154.74M derived: sum of 3 quarters · filed 2026-08-14 | $212.62M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $52.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $105.46M derived: sum of 2 quarters · filed 2026-06-29 | $163.34M derived: sum of 3 quarters · filed 2026-06-29 | $221.18M 10-K · filed 2026-06-29 |
| 2025-12-31 | $53.14M 10-Q · filed 2026-02-03 | $111.02M derived: sum of 2 quarters · filed 2026-02-03 | $168.86M 10-Q · filed 2026-02-03 | $222.84M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $57.88M 10-Q · filed 2025-11-06 | $115.72M 10-Q · filed 2025-11-06 | $169.69M derived: sum of 3 quarters · filed 2026-08-14 | $217.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $57.84M 10-Q · filed 2026-08-14 | $111.82M derived: sum of 2 quarters · filed 2026-08-14 | $159.82M derived: sum of 3 quarters · filed 2026-08-14 | $203.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $53.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $101.98M derived: sum of 2 quarters · filed 2026-06-29 | $145.43M derived: sum of 3 quarters · filed 2026-06-29 | $189.45M 10-K · filed 2026-06-29 |
| 2024-12-31 | $48.00M 10-Q · filed 2026-02-03 | $91.45M derived: sum of 2 quarters · filed 2026-02-03 | $135.47M 10-Q · filed 2026-02-03 | $177.00M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | $43.45M 10-Q · filed 2025-11-06 | $86.42M 10-Q · filed 2025-11-06 | $129.00M derived: sum of 3 quarters · filed 2025-11-06 | $171.85M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $42.97M 10-Q · filed 2025-08-07 | $85.55M derived: sum of 2 quarters · filed 2025-08-07 | $128.40M derived: sum of 3 quarters · filed 2025-08-07 | $177.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $42.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $85.43M derived: sum of 2 quarters · filed 2025-05-22 | $134.53M derived: sum of 3 quarters · filed 2025-05-22 | $174.96M 10-K · filed 2025-05-22 |
| 2023-12-31 | $42.85M 10-Q · filed 2025-02-12 | $91.95M derived: sum of 2 quarters · filed 2025-02-12 | $132.38M 10-Q · filed 2025-02-12 | $170.34M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | $49.10M 10-Q · filed 2024-11-12 | $89.54M 10-Q · filed 2024-11-12 | $127.49M derived: sum of 3 quarters · filed 2024-11-12 | $157.75M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $40.44M 10-Q · filed 2024-08-08 | $78.39M derived: sum of 2 quarters · filed 2024-08-08 | $108.65M derived: sum of 3 quarters · filed 2024-08-08 | $137.49M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $37.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | $68.22M derived: sum of 2 quarters · filed 2024-05-16 | $97.05M derived: sum of 3 quarters · filed 2024-05-16 | $126.53M 10-K · filed 2024-05-16 |
| 2022-12-31 | $30.26M 10-Q · filed 2024-02-08 | $59.09M derived: sum of 2 quarters · filed 2024-02-08 | $88.57M 10-Q · filed 2024-02-08 | $110.31M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | $28.83M 10-Q · filed 2023-11-07 | $58.31M 10-Q · filed 2023-11-07 | $80.05M derived: sum of 3 quarters · filed 2023-11-07 | $99.40M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $29.48M 10-Q · filed 2023-08-03 | $51.21M derived: sum of 2 quarters · filed 2023-08-03 | $70.57M derived: sum of 3 quarters · filed 2023-08-03 | $90.47M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $21.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $41.09M derived: sum of 2 quarters · filed 2023-05-18 | $60.99M derived: sum of 3 quarters · filed 2023-05-18 | $79.55M 10-K · filed 2023-05-18 |
| 2021-12-31 | $19.35M 10-Q · filed 2023-02-09 | $39.26M derived: sum of 2 quarters · filed 2023-02-09 | $57.81M 10-Q · filed 2023-02-09 | $74.03M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $19.90M 10-Q · filed 2022-11-03 | $38.46M 10-Q · filed 2022-11-03 | $54.68M derived: sum of 3 quarters · filed 2022-11-03 | $69.00M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $18.55M 10-Q · filed 2022-08-04 | $34.78M derived: sum of 2 quarters · filed 2022-08-04 | $49.10M derived: sum of 3 quarters · filed 2022-08-04 | $63.15M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $16.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $30.55M derived: sum of 2 quarters · filed 2022-05-19 | $44.60M derived: sum of 3 quarters · filed 2022-05-19 | $56.75M 10-K · filed 2022-05-19 |
| 2020-12-31 | $14.32M 10-Q · filed 2022-02-03 | $28.37M derived: sum of 2 quarters · filed 2022-02-03 | $40.53M 10-Q · filed 2022-02-03 | $51.72M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-09-30 | $14.05M 10-Q · filed 2021-11-04 | $26.21M 10-Q · filed 2021-11-04 | $37.40M derived: sum of 3 quarters · filed 2021-11-04 | $49.34M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $12.16M 10-Q · filed 2021-08-06 | $23.34M derived: sum of 2 quarters · filed 2021-08-06 | $35.29M derived: sum of 3 quarters · filed 2021-08-06 | $43.46M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $23.14M derived: sum of 2 quarters · filed 2021-05-20 | $31.30M derived: sum of 3 quarters · filed 2021-05-20 | $38.76M 10-K · filed 2021-05-20 |
| 2019-12-31 | $11.95M 10-Q · filed 2021-02-04 | $20.12M derived: sum of 2 quarters · filed 2021-02-04 | $27.57M 10-Q · filed 2021-02-04 | $32.99M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | $8.17M 10-Q · filed 2020-11-05 | $15.63M 10-Q · filed 2020-11-05 | $21.04M derived: sum of 3 quarters · filed 2020-11-05 | $28.89M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $7.46M 10-Q · filed 2020-08-07 | $12.87M derived: sum of 2 quarters · filed 2020-08-07 | $20.73M derived: sum of 3 quarters · filed 2020-08-07 | $25.69M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $13.27M derived: sum of 2 quarters · filed 2020-06-03 | $18.23M derived: sum of 3 quarters · filed 2020-06-03 | $22.17M 10-K · filed 2020-06-03 |
| 2018-12-31 | $7.86M 10-Q · filed 2020-02-13 | $12.82M derived: sum of 2 quarters · filed 2020-02-13 | $16.76M 10-Q · filed 2020-02-13 | $21.26M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | $4.96M 10-Q · filed 2019-11-12 | $8.90M 10-Q · filed 2019-11-12 | $13.40M derived: sum of 3 quarters · filed 2020-06-03 | $16.97M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | $3.94M 10-Q · filed 2019-08-14 | $8.44M derived: sum of 2 quarters · filed 2020-06-03 | $12.01M derived: sum of 3 quarters · filed 2020-06-03 | $15.16M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $8.08M derived: sum of 2 quarters · filed 2020-06-03 | $11.22M derived: sum of 3 quarters · filed 2020-06-03 | $13.52M 10-K · filed 2020-06-03 |
| 2017-12-31 | $3.57M 10-Q · filed 2019-02-14 | $6.72M derived: sum of 2 quarters · filed 2019-02-14 | $9.01M 10-Q · filed 2019-02-14 | |
| 2017-09-30 | $3.15M 10-Q · filed 2018-11-14 | $5.44M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $2.29M 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | $6.94M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |